Disease Overview：Atopic Dermatitis（AD）
Atopic dermatitis (AD), a chronic, relapsing inflammatory skin disorder, is characterized by intense pruritus, xerosis, erythema, lichenification, and eczematous lesions—typically affecting flexural areas in adults and extensor surfaces in infants. Driven by complex interactions among genetic predisposition (e.g., FLG gene mutations), immune dysregulation (Th2-skewed inflammation with elevated IL-4, IL-13, IL-31), epidermal barrier dysfunction, and environmental triggers, AD significantly impairs quality of life and often co-occurs with asthma, allergic rhinitis, and food sensitization. Diagnosis relies on clinical criteria (e.g., Hanifin & Rajka or UK Working Party guidelines), supported by serum IgE assessment and patch testing when comorbid contact allergy is suspected. Management follows a stepwise approach: optimized emollient therapy, topical corticosteroids or calcineurin inhibitors for flare control, and systemic interventions—including dupilumab, tralokinumab, lebrikizumab, and JAK inhibitors—for moderate-to-severe cases unresponsive to conventional therapy.
China offers distinct advantages for international patients seeking AD management. Leading dermatology centers—such as Peking Union Medical College Hospital and Shanghai Skin Disease Hospital—host nationally recognized experts with extensive experience in biologics and targeted immunomodulators, backed by state-of-the-art confocal microscopy, non-invasive skin barrier analyzers (e.g., Tewameter®, Corneometer®), and real-world registries demonstrating sustained response rates exceeding 75% at 12 months with newer biologics. Treatment costs remain 40–60% lower than in the US or Western Europe, without compromising clinical rigor or regulatory compliance—China’s NMPA has approved all major AD biologics, and many centers participate in global phase III/IV trials. As a dedicated medical tourism agency, we facilitate seamless access: pre-arrival clinical evaluation, direct coordination with certified dermatologists, transparent itemized pricing (including consultations, diagnostics, medications, and follow-up telemedicine), visa support, multilingual interpretation, and post-treatment care coordination—all designed to reduce logistical uncertainty while prioritizing evidence-based outcomes.
Atopic Dermatitis: treatment in China helps patients compare specialist hospitals, initial assessment steps and estimated costs that may vary by city, institution and clinical condition.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Atopic Dermatitis (Dermatology)
Non-Surgical / Conservative / Medication Options
*Target criteria:* Mild-to-moderate AD, pediatric/adult patients without systemic immunosuppression contraindications.
- •Topical Therapy (First-line)
- Medium-potency (e.g., mometasone 0.1% ointment): $22–$35 per 15g tube - Topical calcineurin inhibitors (tacrolimus 0.03%/0.1% ointment): $48–$72 per 15g tube - Crisaborole 2% ointment: $95–$130 per 60g tube
- •Systemic Pharmacotherapy
- Oral corticosteroids (prednisone taper, ≤2 weeks): $12–$25 total course - Dupilumab (biologic; subcutaneous injection): - Loading dose (600 mg): $1,280 - Maintenance (300 mg q2w): $640/injection → $3,840/year - Tralokinumab (biologic): $1,120/dose → $6,720/year - JAK inhibitors (upadacitinib 15 mg daily): $420–$490/month
- •Diagnostic & Monitoring Fees
- Serum IgE + eosinophil count: $24 - Patch testing (if allergic contact component suspected): $85 - Skin biopsy (rarely needed): $65
Procedural / Interventional Options
*Eligibility:* Severe, refractory AD unresponsive to ≥3 months of optimized topical/systemic therapy; no active infection or uncontrolled comorbidities.
- •Narrowband UVB Phototherapy (311 nm)
- Standard course (2–3×/week × 12–16 weeks): $1,1,550 total - Pre-treatment workup (liver/kidney function, skin exam): $42
- •Cyclosporine Infusion (IV, reserved for acute flares)
- Full 3-month course (max 5 mg/kg/day): $2,900–$3,700 - Pre-infusion labs (CBC, creatinine, LFTs, BP monitoring): $58
Special/Complex Condition Management
- •AD with severe superinfection (e.g., *S. aureus* cellulitis): IV antibiotics (ceftriaxone 1g daily × 7 days): $145–$210 total
- •Pediatric AD (<2 years) requiring biologics: Dupilumab weight-based dosing (≤15 kg): $820–$1,050/dose → $4,900–$6,300/year
- •AD with significant lichenification/scarring: Combination regimen (topical steroids + intralesional triamcinolone 5 mg/mL): $38/injection
Quick Selection Guide
- •Children <6 years, mild AD, budget-conscious: Topical hydrocortisone + emollients ($15–$25/month)
- •Adults, moderate AD, moderate budget: Tacrolimus 0.1% + dupilumab loading + maintenance ($1,920 first year)
- •Severe refractory AD, high severity, insurance-covered: Dupilumab long-term ($3,840/year)
- •Elderly patients with renal impairment: Narrowband UVB ($1,100–$1,550/course) — avoids systemic drug metabolism risks
- •Comorbid asthma Dupilumab preferred (dual indication; $3,840/year**) over JAK inhibitors (higher thrombosis risk)
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Atopic Dermatitis Medical Vacation Packages
Curated transparent all-inclusive packages combining Atopic Dermatitis treatment with China top medical destinations:
